Treatment of POEMS syndrome with bevacizumab.
We report a case of POEMS syndrome which relapsed six years after autologous peripheral blood stem cell transplantation. According to encouraging data published recently, we treated the patient with cyclophosphamide, dexamethasone and the VEGF-antibody bevacizumab. After an initial improvement, the subsequent course was complicated by severe adverse events leading to multiorgan failure and death. This dramatic decline highlights the need for further investigation before using bevacizumab in patients with POEMS syndrome.
Samaras
Panagiotis
P
Bauer
Stefan
S
Stenner-Liewen
Frank
F
Steiner
Rudolf
R
Zweifel
Martin
M
Renner
Christoph
C
Knuth
Alexander
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D016878:POEMS Syndrome / Q000097:blood / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab